COMPANY PROFILE

Syncell

Explore full profile

Innovative spatial biology solutions using AI-guided photolabeling for precise 3D biospecimen analysis

Taipei, TaiwanFounded 2020Biotech & Life Sciences

Valuation $50–100M Last recorded · 2024

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About Syncell

SYNCELL is a startup with the pioneering optoproteomics technology that turns a microscope into a "microscoop" to pick up proteins at specified locations. Integrating microscopy, deep learning, mechatronics, optics, photochemistry, biochemistry, and mass spectrometry with years of development, optoproteomics technology is expected to be indispensable for next-generation biological research, pushing our current limit of whole cell DNA/RNA studies to a new horizon of highly-anticipated whole cell protein studies.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2020
Headquarters: Taipei, Taiwan
Employees: 57
Open positions: None listed
Dealroom signal: 81.6/100
Industry: Health
Sub-industry: Pharmaceutical, BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, proteomics, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

5 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES A✓Equity / VC	Dec 2024	$15M	$60M	Taiwania Capital	↗
CONVERTIBLEEquity / VC	Oct 2023	$8.1M	—	Undisclosed	—

Showing the latest 2 of 5 recorded eventsBook a demo for the full funding history →

Growth signals

Syncell website traffic

Latest recorded traffic for Syncell is 8.3K monthly website visits, up 16.9% over the last three months. Syncell's team declined 1.7% over the past year.

Latest monthly visits8.3K 3-month web change+16.9% 1-year team growth-1.7%

Monthly website visitsOct 2020–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
ETEikonizo TherapeuticsDeveloping therapies to improve the treatment of human disease, specifically neurodegenerative diseases	Cambridge, United States	Operational	13	$43M	$160M
MTMyris TherapeuticsA transformational platform company that develops next-generation nanoarmored protein-polymer conjugates	Pittsburgh, United States	Operational
SBSibylla BiotechFacing the complexity of drug discovery with the power of an innovative approach for meeting unmet medical needs	Bresso, Italy	Operational
TUTubulisGenerates uniquely matched protein-drug conjugates by combining proprietary novel technologies with disease-specific biology	Planegg, Germany	Acquired
CTCyclone TherapeuticsA preclinical-stage drug discovery company that focuses on improving protein quality control by modulating translation	San Diego, United States	Operational
BTBeijing Likang Life TechnologyChina's first personalized neoantigen-targeted cancer vaccine receives NMPA's clinical tri	China	Operational
STSOLID TherapeuticsSOLID Therapeutics is an early-stage oncology company spun out of CBMR at the University of Copenhagen	Copenhagen, Denmark	Operational
VIVicinitasAdvancing a one-of-a-kind protein stabilization platform to develop novel therapeutics for cancer and genetic disorders	South San Francisco, United States	Operational